NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced a partnership with Cure Forward, a company that aims to provide patients greater access to their genomic test results. 

The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials. 

Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.